Intravenously Administered Iduronate-2-Sulfatase Fused with Anti-Human Transferrin Receptor Antibody (Jr-141) Crosses the Blood-Brain Barrier to Address Central Nervous System Disorders in Hunter Syndrome: A Randomised, Open-Label, Phase 1/2 Trial

2018 ◽  
Author(s):  
Torayuki Okuyama ◽  
Yoshikatsu Eto ◽  
Norio Sakai ◽  
Kohtaro Minami ◽  
Tatsuyoshi Yamamoto ◽  
...  
2012 ◽  
Vol 56 (5-6) ◽  
pp. 355
Author(s):  
Christoph Kleinschnitz ◽  
Kinga Blecharz ◽  
Timo Kahles ◽  
Tobias Schwarz ◽  
Peter Kraft ◽  
...  

2007 ◽  
Author(s):  
P. S. Seibert ◽  
P. D. Parker ◽  
C. M. Patterson ◽  
N. Whitener ◽  
J. O'Donnell ◽  
...  

Author(s):  
Asfree Gwanyanya ◽  
Christie Nicole Godsmark ◽  
Roisin Kelly-Laubscher

Abstract: Ethanolamine is a bioactive molecule found in several cells, including those in the central nervous system (CNS). In the brain, ethanolamine and ethanolamine-related molecules have emerged as prodrug moieties that can promote drug movement across the blood-brain barrier. This improvement in the ability to target drugs to the brain may also mean that in the process ethanolamine concentrations in the brain are increased enough for ethanolamine to exert its own neurological ac-tions. Ethanolamine and its associated products have various positive functions ranging from cell signaling to molecular storage, and alterations in their levels have been linked to neurodegenerative conditions such as Alzheimer’s disease. This mini-review focuses on the effects of ethanolamine in the CNS and highlights the possible implications of these effects for drug design.


Sign in / Sign up

Export Citation Format

Share Document